Nuvig Therapeutics in the NEWS
Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, and funds managed by abrdn Inc., and existing shareholders, Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.
Nuvig Therapeutics aims to deliver novel methods that reduce autoimmune dysregulation without immunosuppression.
From Nuvig Therapeutics
Pamela Conley, Ph.D., Cofounder, Chief Scientific Officer, and founding Chief Executive Officer of Nuvig Therapeutics said, “We are delighted to partner with additional high-caliber investors. Their scientific and strategic perspectives will support our efforts to diversify our pipeline and bring potentially transformative medicines to patients.”
The Product NVG-2089
NVG-2089 is the lead candidate, a first-in-class, recombinant, Fc fragment immunomodulator, engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that improves autoimmune dysregulation.
The proceeds from Series B financing will support clinical proof-of-concept studies for NVG-2089 and advance Nuvig’s preclinical pipeline.
Nuvig Therapeutics is progressing NVG-2089 to Phase 2 clinical development in chronic inflammatory demyelinating polyneuropathy (CIDP) and other undisclosed indications for which there is a high unmet need for non-immunosuppressive, efficacious new therapies.
Dosing in the Phase 1 study for NVG-2089 has been completed. In Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies, NVG-2089 was safe and well-tolerated. The pharmacokinetic data were dose-proportional, and pharmacodynamic data demonstrated target engagement. The positive results from Phase 1 support the progression of NVG-2089 to Phase 2 studies across multiple indications.
In conjunction with the financing, Paulina Hill, Ph.D., Partner at Sanofi Ventures, Tim Anderson, Managing Director at Blue Owl Healthcare Opportunities, and Tiba Aynechi, Ph.D., General Partner at Norwest Venture Partners, joined Nuvig’s Board of Directors.
More from the Experts
Dr. Paulina Hill, Ph.D., Partner at Sanofi Ventures, said, “Nuvig’s innovative and immunomodulatory approach to inflammatory and autoimmune diseases is well aligned with Sanofi Ventures’ development and investment philosophy. We are impressed by the detailed progress performed by an accomplished team of scientists and executives at Nuvig. They have not only demonstrated powerful anti-inflammatory effects of their lead candidate NVG-2089 without immunosuppression but have also created a reproducible and scalable recombinant method of recapitulating the effects of IVIg without the downsides and supply limitations of IVIg.”
Mr. Tim Anderson, Managing Director at Blue Owl Healthcare Opportunities Anderson added, “We are happy to partner with Nuvig on the Series B financing and we are very pleased with the recent advancements at Nuvig. In particular, we are excited about Nuvig’s ability to demonstrate that the specific biology of NVG-2089 is engaging the relevant mechanistic pathways in early clinical studies and look forward to further advancing NVG-2089 in the clinic in indications where Nuvig can offer significant advances in safety and efficacy.”
Tiba Aynechi, Ph.D., General Partner at Norwest Venture Partners, concluded, “We are pleased to support Nuvig’s continued progress towards delivering powerful and safe immune-modulating therapies in autoimmune therapeutic areas where there is a significant unmet need. We believe that NVG-2089 has life-changing potential for patients who otherwise have limited treatment options, and Nuvig’s platform programs show promise for applications across a wide range of autoimmune diseases.”
In addition, Nuvig also appointed as independent members of the Nuvig Board of Directors: Ciara Kennedy, Ph.D., founder, President, and CEO of Sorriso Pharmaceuticals, and James Mackay, Ph.D., who most recently was the founder, President, and CEO of Aristea Therapeutics and currently serves as the founder and CEO of Kateran Consulting.
Chronic Inflammatory Demyelinating Polyneuropathy
CIDP is a neurological autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
Typical Symptoms include:
- Symmetrical muscle weakness: This leads to difficulties with walking, climbing stairs, and performing fine motor tasks.
- Sensory disturbances: Numbness, tingling, or burning sensations. Additionally, diminished or absent reflexes are a common clinical finding.
- Frequent Fatigue: Significantly impacting the patient’s quality of life.
- CIDP symptoms: Can vary in severity and may progress over several months.
The diagnosis is typically confirmed through nerve conduction studies, which reveal demyelination, and cerebrospinal fluid analysis showing elevated protein levels.
Nuvig Therapeutics
Nuvig Therapeutics is a clinical-stage biotechnology company that is advancing an innovative and transformational pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
The Lead NVG-2089
NVG-2089 is an engineered Fc fragment designed to precisely target type II Fc receptors. When NVG-2089 binds to its target, it upregulates the expression of FcgRIIb and causes the expansion of T regulatory cells and the downregulation of numerous inflammatory pathways. Nuvig is based in Menlo Park, California.
Prohost Observations
There are approved treatments for autoimmune diseases, but most have terrible adverse events causing the nastiest symptoms, sometimes worse than those from the diseases they intended to treat. Investors in the stock market would ask why we would post a press release of a private firm on our website. Our answer is there are several reasons and they are:
1. Private companies can become publicly traded companies.
2. Investors can invest in private companies by calling the contact media and asking about investing in the firm.
3. By posting private companies aiming at improving treatments, such as Nuvig Therapeutics, alarms the Investors who are betting on approved products that are not sufficiently safe or effective.
That’s why we posted the private Nuvig Therapeutics on our website.
News & Comments
December 5, 2024
Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator
Nuvig Therapeutics in the NEWS
Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, and funds managed by abrdn Inc., and existing shareholders, Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.
Nuvig Therapeutics aims to deliver novel methods that reduce autoimmune dysregulation without immunosuppression.
From Nuvig Therapeutics
Pamela Conley, Ph.D., Cofounder, Chief Scientific Officer, and founding Chief Executive Officer of Nuvig Therapeutics said, “We are delighted to partner with additional high-caliber investors. Their scientific and strategic perspectives will support our efforts to diversify our pipeline and bring potentially transformative medicines to patients.”
The Product NVG-2089
NVG-2089 is the lead candidate, a first-in-class, recombinant, Fc fragment immunomodulator, engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that improves autoimmune dysregulation.
The proceeds from Series B financing will support clinical proof-of-concept studies for NVG-2089 and advance Nuvig’s preclinical pipeline.
Nuvig Therapeutics is progressing NVG-2089 to Phase 2 clinical development in chronic inflammatory demyelinating polyneuropathy (CIDP) and other undisclosed indications for which there is a high unmet need for non-immunosuppressive, efficacious new therapies.
Dosing in the Phase 1 study for NVG-2089 has been completed. In Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies, NVG-2089 was safe and well-tolerated. The pharmacokinetic data were dose-proportional, and pharmacodynamic data demonstrated target engagement. The positive results from Phase 1 support the progression of NVG-2089 to Phase 2 studies across multiple indications.
In conjunction with the financing, Paulina Hill, Ph.D., Partner at Sanofi Ventures, Tim Anderson, Managing Director at Blue Owl Healthcare Opportunities, and Tiba Aynechi, Ph.D., General Partner at Norwest Venture Partners, joined Nuvig’s Board of Directors.
More from the Experts
Dr. Paulina Hill, Ph.D., Partner at Sanofi Ventures, said, “Nuvig’s innovative and immunomodulatory approach to inflammatory and autoimmune diseases is well aligned with Sanofi Ventures’ development and investment philosophy. We are impressed by the detailed progress performed by an accomplished team of scientists and executives at Nuvig. They have not only demonstrated powerful anti-inflammatory effects of their lead candidate NVG-2089 without immunosuppression but have also created a reproducible and scalable recombinant method of recapitulating the effects of IVIg without the downsides and supply limitations of IVIg.”
Mr. Tim Anderson, Managing Director at Blue Owl Healthcare Opportunities Anderson added, “We are happy to partner with Nuvig on the Series B financing and we are very pleased with the recent advancements at Nuvig. In particular, we are excited about Nuvig’s ability to demonstrate that the specific biology of NVG-2089 is engaging the relevant mechanistic pathways in early clinical studies and look forward to further advancing NVG-2089 in the clinic in indications where Nuvig can offer significant advances in safety and efficacy.”
Tiba Aynechi, Ph.D., General Partner at Norwest Venture Partners, concluded, “We are pleased to support Nuvig’s continued progress towards delivering powerful and safe immune-modulating therapies in autoimmune therapeutic areas where there is a significant unmet need. We believe that NVG-2089 has life-changing potential for patients who otherwise have limited treatment options, and Nuvig’s platform programs show promise for applications across a wide range of autoimmune diseases.”
In addition, Nuvig also appointed as independent members of the Nuvig Board of Directors: Ciara Kennedy, Ph.D., founder, President, and CEO of Sorriso Pharmaceuticals, and James Mackay, Ph.D., who most recently was the founder, President, and CEO of Aristea Therapeutics and currently serves as the founder and CEO of Kateran Consulting.
Chronic Inflammatory Demyelinating Polyneuropathy
CIDP is a neurological autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
Typical Symptoms include:
The diagnosis is typically confirmed through nerve conduction studies, which reveal demyelination, and cerebrospinal fluid analysis showing elevated protein levels.
Nuvig Therapeutics
Nuvig Therapeutics is a clinical-stage biotechnology company that is advancing an innovative and transformational pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
The Lead NVG-2089
NVG-2089 is an engineered Fc fragment designed to precisely target type II Fc receptors. When NVG-2089 binds to its target, it upregulates the expression of FcgRIIb and causes the expansion of T regulatory cells and the downregulation of numerous inflammatory pathways. Nuvig is based in Menlo Park, California.
For more information, please visit www.nuvigtherapeutics.com.
Contacts
Corporate: [email protected]/
Media: Jessica Yingling, Ph.D., +1.858.344.8091. Little Dog Communications Inc., [email protected],
Prohost Observations
There are approved treatments for autoimmune diseases, but most have terrible adverse events causing the nastiest symptoms, sometimes worse than those from the diseases they intended to treat. Investors in the stock market would ask why we would post a press release of a private firm on our website. Our answer is there are several reasons and they are:
1. Private companies can become publicly traded companies.
2. Investors can invest in private companies by calling the contact media and asking about investing in the firm.
3. By posting private companies aiming at improving treatments, such as Nuvig Therapeutics, alarms the Investors who are betting on approved products that are not sufficiently safe or effective.
That’s why we posted the private Nuvig Therapeutics on our website.
Other Articles